[Translation] A Phase I clinical study evaluating the safety, tolerability, and dose escalation and dose expansion of GTA182 in patients with MTAPnull/lost advanced solid tumors.

Ia期（剂量递增阶段）（1）主要目的：评估GTA182在MTAPnull/lost晚期实体瘤受试者中的安全性和耐受性，以确定扩展期推荐剂量（RDEs）或最大耐受剂量（MTD）（如存在）。（2）次要目的：评估GTA182在MTAPnull/lost晚期实体瘤受试者中的药代动力学特征；评估GTA182在MTAPnull/lost晚期实体瘤受试者中的初步有效性。（3）探索性目的：探索与GTA182疗效相关的生物标志物。Ib期（剂量扩展阶段）（1）主要目的：评估在RDEs剂量下GTA182在MTAPnull/lost晚期实体瘤受试者中的安全性和耐受性，以确认II期推荐剂量（RP2D）。（2）次要目的：评估在RDEs剂量下GTA182在MTAPnull/lost晚期实体瘤受试者中的药代动力学特征；评估在RDEs剂量下GTA182在MTAPnull/lost晚期实体瘤受试者中的初步有效性，为后续临床试验推荐剂量和适应症选择提供依据。（3）探索性目的：探索与GTA182疗效相关的生物标志物。

[Translation]

Phase Ia (Dose Escalation Phase) (1) Primary Objective: To assess the safety and tolerability of GTA182 in patients with MTAPnull/lost advanced solid tumors to determine the recommended dose (RDEs) or maximum tolerated dose (MTD) for the extended phase (if applicable). (2) Secondary Objective: To assess the pharmacokinetic characteristics of GTA182 in patients with MTAPnull/lost advanced solid tumors; to assess the preliminary efficacy of GTA182 in patients with MTAPnull/lost advanced solid tumors. (3) Exploratory Objective: To explore biomarkers related to the efficacy of GTA182. Phase Ib (Dose Expansion Phase) (1) Primary Objective: To assess the safety and tolerability of GTA182 at RDEs in patients with MTAPnull/lost advanced solid tumors to confirm the recommended dose (RP2D) for the phase II phase. (2) Secondary objectives: To evaluate the pharmacokinetic characteristics of GTA182 at RDE doses in MTAPnull/lost advanced solid tumor subjects; to evaluate the preliminary efficacy of GTA182 at RDE doses in MTAPnull/lost advanced solid tumor subjects, providing a basis for recommended doses and indications selection in subsequent clinical trials. (3) Exploratory objectives: To explore biomarkers related to the efficacy of GTA182.

Start Date30 Oct 2024

Sponsor / Collaborator

Shanghai Pailong Biotechnology Co., Ltd.

CTR20254181

/ Not yet recruitingPhase 1

评价GTA182联合伏美替尼在MTAP纯合型缺失的局部晚期或转移性非小细胞肺癌（NSCLC）受试者中的安全性、耐受性、药代动力学以及初步有效性的剂量递增和剂量扩展的I期临床研究

[Translation] A phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and initial efficacy of GTA182 in combination with vortexinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) homozygous absence of MTAP.

Ia期（剂量递增阶段）主要目的：评估GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的安全性和耐受性，以确定扩展期推荐的联合剂量。次要目的：描述GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的药代动力学特征；评估GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的初步有效性。探索性目的：探索与GTA182疗效相关的生物标志物。 Ib期（剂量扩展阶段）主要目的：评估在Ia期推荐的联合剂量下GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的安全性和耐受性，以确认联合用药RP2D。次要目的：评估在Ia期推荐的联合剂量下GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的药代动力学特征；评估在Ia期推荐的联合剂量下GTA182联合伏美替尼在MTAP纯合型缺失局部晚期或转移性NSCLC受试者中的初步有效性，为后续临床试验推荐剂量选择提供依据。探索性目的：探索与GTA182疗效相关的生物标志物。

[Translation]

Phase Ia (Dose Escalation Phase) Primary Objective: To evaluate the safety and tolerability of GTA182 in combination with voreminib in patients with MTAP homozygous deletion locally advanced or metastatic NSCLC to determine the recommended combination dose for the extension phase. Secondary Objectives: To describe the pharmacokinetic characteristics of GTA182 in combination with voreminib in patients with MTAP homozygous deletion locally advanced or metastatic NSCLC; to assess the preliminary efficacy of GTA182 in combination with voreminib in patients with MTAP homozygous deletion locally advanced or metastatic NSCLC. Exploratory Objectives: To explore biomarkers related to the efficacy of GTA182. Phase Ib (Dose Extension Phase) Primary Objective: To evaluate the safety and tolerability of GTA182 in combination with voreminib at the Phase Ia recommended combination dose in patients with MTAP homozygous deletion locally advanced or metastatic NSCLC to confirm the RP2D of the combination therapy. Secondary objectives: To evaluate the pharmacokinetic characteristics of GTA182 in combination with vortexinib at the recommended combination dose in Phase Ia patients with MTAP homozygous deletion locally advanced or metastatic NSCLC; to assess the preliminary efficacy of GTA182 in combination with vortexinib at the recommended combination dose in Phase Ia patients with MTAP homozygous deletion locally advanced or metastatic NSCLC, providing a basis for dose selection in subsequent clinical trials. Exploratory objectives: To explore biomarkers associated with the efficacy of GTA182.

Start Date-

Sponsor / Collaborator

Shanghai Pailong Biotechnology Co., Ltd.

100 Clinical Results associated with GTA-182

100 Translational Medicine associated with GTA-182

100 Patents (Medical) associated with GTA-182

100 Deals associated with GTA-182

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 1	China	Shanghai Pailong Biotechnology Co., Ltd.	30 Oct 2025
Methylthioadenosine phosphorylase deletion cancer	Phase 1	China	Shanghai Pailong Biotechnology Co., Ltd.	19 Nov 2024
Advanced Malignant Solid Neoplasm	Phase 1	China	Shanghai Pailong Biotechnology Co., Ltd.	30 Oct 2024
Locally Advanced Lung Non-Small Cell Carcinoma	IND Approval	China	Shanghai Pailong Biotechnology Co., Ltd.	29 Sep 2025
metastatic non-small cell lung cancer	IND Approval	China	Shanghai Pailong Biotechnology Co., Ltd.	29 Sep 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTR20243795 (ESMO_ASIA2025 \| GlobeNewswire) Manual	Phase 1	Advanced Lung Non-Small Cell Carcinoma \| Methylthioadenosine phosphorylase deletion cancer MTAP Deletion	41	GTA182 (MTAP-deleted advanced solid tumors, all doses)	klnhrbtmoz(dckskvcwmm) = hltzzbffxv ducdwhtubp (vkimcxmebn ) View more	Positive	05 Dec 2025
				GTA182 (MTAP-deleted NSCLC, efficacy-evaluable at active doses)	hcbpcrsqwa(rruspqhtcn) = kuwdmczyqi sfdkpfuyfm (tssfxzbces, 21.2 - 86.3) View more
CTR20243795 (Company_Website) Manual	Phase 1	Advanced Lung Non-Small Cell Carcinoma \| Methylthioadenosine phosphorylase deletion cancer MTAP deletion	41	GTA182 (MTAP-deleted advanced solid tumors, all doses)	zvogmykkqy(fdrtziwhaf) = The most frequent TRAEs being anemia (51.2%), decreased appetite (43.9%), and asthenia (39.0%). cldryegptn (vitmajhscs ) View more	Positive	05 Dec 2025
				GTA182 (MTAP-deleted NSCLC, efficacy-evaluable at active doses)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

GTA-182

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation